Premium
Immunohistochemical evaluation of MYC expression in mantle cell lymphoma
Author(s) -
Oberley Matthew J,
Rajguru Saurabh A,
Zhang Chong,
Kim KyungMann,
Shaw Gene R,
Grindle Kreg M,
Kahl Brad S,
Kanugh Craig,
Laffin Jennifer,
Yang David T
Publication year - 2013
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.12207
Subject(s) - immunohistochemistry , mantle cell lymphoma , hazard ratio , tissue microarray , international prognostic index , spearman's rank correlation coefficient , medicine , lymphoma , correlation , pathology , blastoid , oncology , biology , confidence interval , diffuse large b cell lymphoma , statistics , mathematics , geometry
Aim To assess the validity and potential clinical utility of evaluating MYC expression by immunohistochemistry ( IHC ) in mantle cell lymphoma ( MCL ). Methods and results MYC IHC was scored on a tissue microarray containing 62 MCL s and 29 controls by two pathologists. Inter‐observer correlation was high (intra‐class correlation of 0.98). MYC IHC scores correlated with MYC expression (Spearman's rank correlation 0.69, P < 0.0001) and weakly with Ki67 proliferation index (Spearman's rank correlation 0.30, P = 0.03). Six blastic MCLs did not have higher mean MYC IHC scores or MYC mRNA expression than non‐blastic MCL s. None of 57 cases assessed, including all of the blastic cases, showed MYC rearrangement by fluorescence in‐situ hybridization. Multivariate analysis with backward selection from potential predictors including age, lactate dehydrogenase, leukocyte count, MIPI score, ECOG performance status, blastic morphology and Ki67 index showed that MYC IHC score is an independent predictor of progression‐free survival (hazard ratio 2.34, 95% CI 1.42–3.88, P = 0.0009) and overall survival (hazard ratio 1.90, 95% CI 1.05–3.43, P = 0.034). Conclusions We show that a new monoclonal anti‐ MYC antibody can enable accurate and reproducible visual assessment of MYC expression that is independently predictive of clinical outcomes in MCL .